ORGANON & CO Stock Price, News & Analysis

Organon (NYSE: OGN) is set to release its Q1 2023 financial results on May 4, 2023, before a scheduled webcast and conference call at 8:30 a.m. EDT. The live call can be accessed via the company's website, with a replay available two hours post-event. Institutional investors and analysts must register in advance to join the call.

Organon, headquartered in Jersey City, New Jersey, focuses on women's health, offering over 60 products across various therapeutic areas. The company aims to invest in innovation and strengthen its global presence, supporting growth and collaboration opportunities in the biopharmaceutical sector.

On April 19, 2023, Lifezone Metals announced the initiation of an off-take marketing process for nickel, copper, and cobalt from its Kabanga Project, believed to be among the world's largest and highest-grade nickel deposits. This move follows a Business Combination Agreement with GoGreen Investments Corporation (NYSE: GOGN). Lifezone aims to support the clean energy transition through its proprietary Hydromet Technology, which offers a low-carbon alternative to traditional smelting. The company holds marketing rights for up to 40% of the Kabanga Project's total production. RBC Capital Markets will oversee the marketing process, which is critical for monetizing the project amid rising demand from electric vehicle and battery manufacturers.

Organon (NYSE: OGN) has launched a global initiative named “Her Plan is Her Power” with a funding of $30 million aimed at addressing unplanned pregnancies, which affect approximately 121 million women and girls yearly. This initiative extends from the previous FP2030 commitment and focuses on improving access to contraceptive services. The multi-year program (2023-2025) includes collaborations with UNFPA and grants to local organizations across 13 countries. The initiative was announced on International Women’s Day, highlighting the urgent need for public health solutions in women’s reproductive health.

Organon (NYSE: OGN) reported full-year 2022 revenues of $6.2 billion, a 2% decrease from 2021. Women's Health revenue grew 4% to $1.7 billion, driven by Nexplanon, while Biosimilars increased 13% to $481 million. Established Brands experienced a 5% revenue decline to $3.9 billion.

Adjusted EBITDA was $2.1 billion with an EBITDA margin of 33.8%. The diluted earnings per share from continuing operations fell to $3.59, down 32% from 2021. For 2023, revenue guidance ranges from $6.150 billion to $6.450 billion.

Organon (NYSE: OGN) emphasizes the critical need for increased investment in women's health ahead of International Women's Day on March 8. The company highlights that only 1% of healthcare research targets conditions unique to women. As part of its commitment, Organon provides paid time off for its 10,000 employees globally, including 400 in the MENAT region, to advocate for women's health. Key areas of concern include menopause, maternal health, and endometriosis, with calls to engage stakeholders in addressing these issues. Organon aims to stimulate dialogue and action to improve women's health outcomes.